# The Cooper Companies, Inc. (COO) Stock Analysis: Navigating a 9.37% Upside Potential in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-navigating-a-9-37-upside-potential-in-the-healthcare-sector/4121231711
- Published: 2025-12-22T11:20:37+00:00
- Author: Madison Wilson

The Cooper Companies, Inc. (NYSE: COO) stands as a prominent player in the healthcare
sector, specifically within the medical instruments and supplies industry. With 
a market capitalization of $16.45 billion, the San Ramon, California-based company
is a formidable entity known for its innovative solutions in the eye care and women’s
health domains.

Currently trading at $82.75, The Cooper Companies has experienced a modest price
change of $0.29, maintaining stability in an otherwise volatile market. The stock’s
52-week range, spanning from $64.32 to $99.45, highlights its growth potential as
it navigates a competitive landscape. The company’s forward P/E ratio of 16.74 indicates
moderate investor expectations regarding its future earnings performance, though
the lack of trailing P/E and other valuation metrics like PEG, Price/Book, and EV/
EBITDA suggest a need for deeper financial analysis.

Investors will note The Cooper Companies’ revenue growth of 4.60%, a positive indicator
of its capacity to expand in a highly specialized field. With an EPS of 1.87 and
a return on equity of 4.59%, the company demonstrates a careful balance between 
profitability and reinvestment into its operations. The substantial free cash flow
of $376.6 million further underscores its financial health, providing a buffer for
strategic investments and operational flexibility.

Despite the absence of a dividend yield and a payout ratio fixed at 0.00%, The Cooper
Companies has managed to capture the attention of analysts, securing 10 buy ratings,
7 hold ratings, and a single sell rating. The target price range between $71.00 
and $100.00, with an average target of $90.50, suggests a potential upside of 9.37%.
This presents an appealing opportunity for investors seeking exposure to a stable
yet growth-oriented entity within the healthcare sector.

From a technical perspective, the stock’s RSI of 43.03 suggests it is approaching
oversold territory, which may be attractive for value-focused investors. The MACD
of 2.50 compared to the signal line of 2.33 reflects bullish sentiment, indicating
a potential positive price movement in the near term. Additionally, the stock’s 
position above both its 50-day and 200-day moving averages ($74.51 and $74.42 respectively)
reinforces a positive technical outlook.

The Cooper Companies operates through two main segments: CooperVision and CooperSurgical.
CooperVision provides a range of contact lenses addressing various vision challenges,
while CooperSurgical focuses on family and women’s health care, offering fertility
products, medical devices, and genomic services. This dual-segment structure not
only diversifies its revenue streams but also positions the company to capitalize
on growing demand in both eye care and women’s health.

Founded in 1958, The Cooper Companies has a long-standing reputation for quality
and innovation. As it continues to expand its market presence, investors would do
well to consider the company’s strategic positioning within the healthcare sector,
robust financial health, and promising growth prospects. The potential 9.37% upside,
backed by strong analyst support, underscores the company’s appeal as a compelling
investment opportunity.

Share on: